Dr. Linda W. Chan, MD

Dr. Chan practices at Memorialcare Radiation Oncology - HOPD in Laguna Hills, California.

Dr. Chan's NPI, 1083844427, was assigned on July 20, 2009. Dr. Chan graduated from Harvard Medical School in 2004. Dr. Chan's California license number on file is A95324.

Dr. Chan's primary practice is Memorialcare Radiation Oncology - HOPD, at 24302 Paseo De Valencia, Laguna Hills, CA 92653.

Dr. Chan's primary practice is Memorialcare Radiation Oncology - HOPD in Laguna Hills, California. Dr. Chan is also affiliated with MemorialCare Saddleback Medical Center. The medical group on file is MemorialCare Medical Group. Dmand AI also links Dr. Chan to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chan practices, 7 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Chan's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Chan is board certified in radiation oncology by the American Board of Radiology. Dr. Chan has a license on file in California.

Dmand AI lists bone cancer radiation, brain cancer radiation, breast cancer radiation, lung cancer radiation, lymphoma radiation and prostate cancer radiation among the conditions Dr. Chan treats.

CMS data shows 459 Medicare services from Dr. Chan across 10 procedure codes in 2024, for 92 Medicare patients. Medicare paid $30,982 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 92 Medicare patients who saw Dr. Chan in 2024. The largest group is 65 to 74, with 54 patients. 75% of them have cancer, and 74% have high cholesterol. Their average risk score is 1.20, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Chan's median patient age at 74, with 52% women.

In 2024, Dr. Chan wrote 74 Medicare Part D claims for 40 patients. 85% of them were for generic drugs. CMS names the drug for 34 of them, across 1 drug with 11 or more claims each, at $781 in total drug cost. In 2023, CMS named 160 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Chan for performance year 2024, reported as part of a group. Dr. Chan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chan as offering telehealth.

Dmand AI links 11 papers to Dr. Chan, published from 2008 to 2010. 2008 was the busiest year, with 3. The most frequent topics are Breast Neoplasms, Mastectomy and Prostatic Neoplasms. Dr. Chan has published most often in Int J Radiat Oncol Biol Phys. Dr. Chan's most frequent co-authors are Mack Roach, MD, Michael D. Alvarado, MD and Alison J. Bevan, MD.

Dmand AI links Dr. Chan to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Prostatic Neoplasms and Prostatic Diseases.

CMS Open Payments shows 42 general payments to Dr. Chan from 17 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 88% of the total. Novocure Inc. paid the most, $492.

Dr. Chan graduated from Harvard Medical School in 2004.

Dr. Chan is in network with 17 carriers, including Blue Cross Blue Shield of Michigan, United Healthcare and Elevance. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.